.css-1xsl8rf{width:100%;display:-webkit-box;display:-webkit-flex;display:-ms-flexbox;display:flex;-webkit-align-items:center;-webkit-box-align:center;-ms-flex-align:center;align-items:center;position:relative;overflow:hidden;background:var(--alert-bg);-webkit-padding-start:var(--chakra-space-4);padding-inline-start:var(--chakra-space-4);-webkit-padding-end:var(--chakra-space-4);padding-inline-end:var(--chakra-space-4);padding-top:var(--chakra-space-1);padding-bottom:var(--chakra-space-1);--alert-fg:var(--chakra-colors-orange-600);--alert-bg:var(--chakra-colors-orange-100);font-weight:var(--chakra-fontWeights-semibold);padding-left:var(--chakra-space-4);}.chakra-ui-dark .css-1xsl8rf:not([data-theme]),[data-theme=dark] .css-1xsl8rf:not([data-theme]),.css-1xsl8rf[data-theme=dark]{--alert-fg:var(--chakra-colors-orange-200);--alert-bg:rgba(251, 211, 141, 0.16);}@media screen and (min-width: 48em){.css-1xsl8rf{padding-left:var(--chakra-space-8);}}Please enable Javascript to use all features and improve your user experience.

ePoster
P102

Evaluating the efficacy of monoclonal antibodies targeting CGRP in migraine treatment and the effect of combination therapy with Onabotulinum Toxin Type-A – a retrospective study

Appointment

Date: 05.12.

Time: 11:50 – 11:55

Talk time: 3 Min.

Discussion time: 2 Min.

Location / Stream:

ePoster station 1

Poster

Evaluating the efficacy of monoclonal antibodies targeting CGRP in migraine treatment and the effect of combination therapy with Onabotulinum Toxin Type-A – a retrospective study

Session

ePoster 01

Topic

CGRP (receptor) inhibitors in the clinic